Nephros (NEPH) to Release Earnings on Thursday

Nephros (NASDAQ:NEPH) is anticipated to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $3.8660 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last released its earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.04. The company had revenue of $4.40 million during the quarter, compared to analysts’ expectations of $3.60 million. Nephros had a return on equity of 14.89% and a net margin of 7.95%.

Nephros Price Performance

NEPH opened at $5.45 on Thursday. The firm has a 50 day simple moving average of $4.61 and a 200 day simple moving average of $3.67. The company has a market cap of $57.77 million, a price-to-earnings ratio of 45.42 and a beta of 1.32. Nephros has a fifty-two week low of $1.39 and a fifty-two week high of $5.98.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Nephros to a “strong-buy” rating in a research report on Saturday, October 18th. Finally, Maxim Group raised their price objective on Nephros from $4.50 to $6.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.50.

Hedge Funds Weigh In On Nephros

An institutional investor recently raised its position in Nephros stock. Topline Capital Management LLC lifted its stake in shares of Nephros Inc. (NASDAQ:NEPH) by 13.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 477,449 shares of the company’s stock after acquiring an additional 55,360 shares during the quarter. Topline Capital Management LLC owned approximately 4.50% of Nephros worth $1,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.